Science Reviews - Biology, 2024, 3(2), 1-12 Aishani Kumar, Thendral Yalini, Sunil Kumar C
Unlocking Cellular Control: The Promise of PROTACs
in Disease Intervention
Aishani Kumar, Thendral Yalini, Sunil Kumar C
Affiliated with PES University, Bangalore, India;,,
1. Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019). Cereblon versus VHL:
Hijacking E3 ligases against each other using PROTACs. Bioorganic & Medicinal Chemistry, 27(12),
24662479. doi:10.1016/j.bmc.2019.02.048
2. Khodavirdipour, Amir, et al. "Apoptosis detection methods in diagnosis of cancer and their
potential role in treatment: advantages and disadvantages: a review." Journal of Gastrointestinal
Cancer 52 (2021): 422-430
3. Troup, Robert I., Charlene Fallan, and Matthias GJ Baud. "Current strategies for the design of
PROTAC linkers: a critical review." Exploration of Targeted Anti-tumor Therapy 1.5 (2020): 273.
4. Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020). Degradation of proteins by PROTACs and
other strategies. Acta Pharmaceutica Sinica. B, 10(2), 207238. doi:10.1016/j.apsb.2019.08.001
5. Rutqvist, L. E. "Radiation therapies for breast cancer: current knowledge on advantages and
disadvantages." Adjuvant Therapy of Breast Cancer IV (1993):
6. Reddy Chichili, V. P., Kumar, V., & Sivaraman, J. (2013). Linkers in the structural biology of
proteinprotein interactions. Protein Science: A Publication of the Protein Society, 22(2), 153167.
7. Sang, Y., Yan, F., & Ren, X. (2015). The role and mechanism of CRL4 E3 ubiquitin ligase in cancer
and its potential therapy implications. Oncotarget, 6(40), 4259042602. doi:10.18632/oncotarget.6052
8. Vittal, V., Stewart, M., Brzović, P. S., & Klevit, R. E. (2015). Regulating the regulators: Recent
revelations in the control of E3 ubiquitin ligases. Journal of Biological Chemistry, 290(35), 21244
9. Garber, Ken. "The PROTAC gold rush." Nat. Biotechnol 40.1 (2022): 12-16.
10. Békés, Miklós, David R. Langley, and Craig M. Crews. "PROTAC targeted protein degraders:
the past is prologue." Nature Reviews Drug Discovery 21.3 (2022): 181-200.
11. Paiva, Stacey-Lynn, and Craig M. Crews. "Targeted protein degradation: elements of PROTAC
design." Current opinion in chemical biology 50 (2019): 111-119.
12. Nalawansha, Dhanusha A., and Craig M. Crews. "PROTACs: an emerging therapeutic modality
in precision medicine." Cell chemical biology 27.8 (2020): 998-1014.
13. Li, Ke, and Craig M. Crews. "PROTACs: past, present and future." Chemical Society Reviews 51.12
(2022): 5214-5236
14. Liu, Jing, et al. "PROTACs: A novel strategy for cancer therapy." Seminars in Cancer Biology.
Vol. 67. Academic Press, 2020.
15. Li, Xintong, et al. "c-Myc-targeting PROTAC based on a TNA-DNA bivalent binder for
combination therapy of triple-negative breast cancer." Journal of the American Chemical Society
145.16 (2023): 9334-9342.
Aishani Kumar, Thendral Yalini, Sunil Kumar C Science Reviews - Biology, 2024, 3(2), 1-12
16. Toure, Momar, and Craig M. Crews. "Smallmolecule PROTACS: new approaches to protein
degradation." Angewandte Chemie International Edition 55.6 (2016): 1966-1973.
17. Ebrahimi, Mehdi, et al. "Synthesis and characterization of biomimetic bioceramic nanoparticles
with optimized physicochemical properties for bone tissue engineering." Journal of Biomedical
Materials Research Part A 107.8 (2019): 1654-1666.
18. Neklesa, Taavi, et al. "ARV-110: An oral androgen receptor PROTAC degrader for prostate
cancer." J. Clin. Oncol 37.259 (2019): 10-1200.
19. Raina, Kanak, et al. "PROTAC-induced BET protein degradation as a therapy for castration-
resistant prostate cancer." Proceedings of the National Academy of Sciences 113.26 (2016): 7124-7129.
20. Snyder, Lawrence B., et al. "The discovery of ARV-471, an orally bioavailable estrogen receptor
degrading PROTAC for the treatment of patients with breast cancer." Cancer Res 81.13 (2021): 44.
21. Pöstges, Florian, et al. "Solubility enhanced formulation approaches to overcome oral delivery
obstacles of PROTACs." Pharmaceutics 15.1 (2023): 156.
22. Benowitz, Andrew B., Paul T. Scott-Stevens, and John D. Harling. "Challenges and opportunities
for in vivo PROTAC delivery." Future Medicinal Chemistry 14.3 (2022): 119-121.
23. Chen, Yu, et al. "Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein
degraders towards clinical translation." Chemical Society Reviews 51.13 (2022): 5330-5350.
24. Ebrahimi, M., Botelho, M., Lu, W., & Monmaturapoj, N. (2019). Synthesis and characterization of
biomimetic bioceramic nanoparticles with optimized physicochemical properties for bone tissue
engineering. Journal of Biomedical Materials Research Part A, 107(7), 1461-1472.
25. Moon, Y.; Jeon, S.I.; Shim, M.K.; Kim, K. Cancer-Specific Delivery of Proteolysis-Targeting
Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics 2023,
15, 411.
26. Zhang, X., Chen, G., Zhang, H., Shang, L., & Zhao, Y. (2023). Bioinspired oral delivery devices.
Nature Reviews Bioengineering, 1, 208225.
27. Békés, M., Langley, D.R. & Crews, C.M. PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov 21, 181200 (2022).
28. Kou, Ponien, et al. "Development of Liposome Systems for Enhancing the PK Properties of
Bivalent PROTACs." Pharmaceutics 15.8 (2023): 2098.
29. Juan, Alberto, et al. "Options to improve the action of PROTACs in cancer: development of
controlled delivery nanoparticles." Frontiers in Cell and Developmental Biology 9 (2022): 805336.
30. Deng, Yuanfei, et al. "ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress
hepatocellular carcinoma progression." Frontiers in Pharmacology 13 (2022): 858901.
31. Schott, Anne F., et al. "Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER)
degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative
breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study." Cancer Research
83.5_Supplement (2023): GS3-03.